A. For	Equity Issues Name of the Issuer: Jeena Sikho Lifecare Limited	
1.	Type of issue (IPO/ FPO	SME IPO
2.	Issue size (Rs Lakh)	Rs. 5,550.00 Lakh
3.	Grade of issue along with name of the rating agency	Not Applicable as IPO on SME Platform of NSE
4.	Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.	2.24 times
5.	QIB holding (as a % of total outstanding capital) as disclosed to stock exchange. (i) allotment in the issue (ii) at the end of the 1st Quarter immediately after the listing of the issue (iii) at the end of 1st FY (iv) at the end of 2nd FY (v) at the end of 3rd FY	Nil Nil Nil Nil

6. Financials of the issuer (as per the annual consolidated financial results submitted to stock exchange)

(Rs. in Lakhs)

Parameters	September 30, 2021	FY21	FY20	FY19
Income from operations	7,131.25	13,580.82	9,441.70	10,581.95
Net Profit for the period	621.53	1,015.57	572.58	599.73
Paid-up equity share capital	1,011.12	10.14	10.00	10.00
Reserves excluding revaluation reserves	2,150.64	2,397.19	1,362.76	790.18

7. Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)
 (i) at the end of 1st FY
 Not Ascertainable as the Company got Listed on

(ii) at the end of 2nd FY (iii) at the end of 3rd FY Not Ascertainable as the Company got Listed on April 19, 2022 Frequently traded Frequently traded

8. Change, if any, in directors of issuer from the disclosures in the offer document

 9. Status of implementation of project/ commencement of commercial production (as submitted to stock exchange) as disclosed in the offer document Actual implementation Reasons for delay in implementation, if any 10. Status of utilization of issue proceeds (as submitted to stock exchange) (i) as disclosed in the offer document (ii) Actual utilization (iii) Reasons for deviation, if any 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document (iii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document (iii) Any other reservations expressed by the monitoring agency about the end use of funds 		 (i) at the end of 1st FY (ii) at the end of 2nd FY (iii) at the end of 3rd FY 	No Change No Change Mr. Chandan Kumar Kaushal is being appointed as a Additional Director w.e.f. April 29,2024.
Actual implementation Not Applicable Reasons for delay in implementation, if any Not Applicable 10. Status of utilization of issue proceeds (as submitted to stock exchange) 5,550 Lakh (i) as disclosed in the offer document 5,550 Lakh (ii) Actual utilization 5,550 Lakh (iii) Reasons for deviation, if any To Purchase Land for setting up/building hospitals/Clinics 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) Not Applicable (i) Comments on use of funds Not Applicable Not Applicable (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer Not Applicable Not Applicable	9.	Status of implementation of project/ commencement of commercial production (as submitted to stock	exchange)
Reasons for delay in implementation, if any Not Applicable 10. Status of utilization of issue proceeds (as submitted to stock exchange) (i) as disclosed in the offer document (ii) Actual utilization 5,550 Lakh (iii) Actual utilization (iii) Reasons for deviation, if any 5,550 Lakh 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document Not Applicable		as disclosed in the offer document	Not Applicable
 10. Status of utilization of issue proceeds (as submitted to stock exchange) (i) as disclosed in the offer document (ii) Actual utilization (iii) Reasons for deviation, if any 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document 		Actual implementation	Not Applicable
 (i) as disclosed in the offer document (ii) Actual utilization (iii) Actual utilization (iii) Reasons for deviation, if any To Purchase Land for setting up/building hospitals/Clinics 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document 		Reasons for delay in implementation, if any	Not Applicable
 (ii) Actual utilization (iii) Reasons for deviation, if any 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document 	10.	Status of utilization of issue proceeds (as submitted to stock exchange)	
 (iii) Reasons for deviation, if any To Purchase Land for setting up/building hospitals/Clinics 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document 		(i) as disclosed in the offer document	5,550 Lakh
11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) hospitals/Clinics (i) Comments on use of funds Not Applicable (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document Not Applicable		(ii) Actual utilization	5,550 Lakh
 11. Comments of monitoring agency, if applicable (See Regulation 262 of SEBI (ICDR) Regulations, 2018) (i) Comments on use of funds (ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document Not Applicable Not Applicable		(iii) Reasons for deviation, if any	To Purchase Land for setting up/building
2018)(i) Comments on use of fundsNot Applicable(ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer documentNot Applicable			hospitals/Clinics
(ii) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer Not Applicable document	11.		
document		(i) Comments on use of funds	Not Applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds Not Applicable			Not Applicable
		(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not Applicable

- 12. Price- related data
 - Issue price (Rs):

150 per equity share

		At close of 30th	At close of 90th calendar day	As at the e the lis	nd of 1st I sting of the			the end of 2 er the listin issue		As at t af	rd FY ng of the	
Price parameters	At close of listing day	calendar day from listing day	from listing day	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price	173.35	150.25	152.40	289.70	194	127	841.65	1500	297	2182.70	2498.60	870

Index (of the Designated Stock Exchange):	16958.65	15809.40	16340.55	17359.75	18887.60	15382.50	22326.90	22526.60	17312.80	23519.35*	26277.35	21281.45
Sectoral Index (NSE SME IPO Index)	NA	N A	NA									

* As on last trading day of the Financial Year i.e. 28-03-2025

13. **Basis for Issue Price and Comparison with Peer Group** (Source of accounting ratios of peer group may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
EDG	Issuer	10.04	24.82	27.84	NA
EPS	Peer Group				
	Kerala Ayurveda Ltd	-4.38	3.09	-0.28	NA
P/E	Issuer	14.93	11.67	30.23	NA
P/E	Peer Group				
	Kerala Ayurveda Ltd	-11.72	26.98	-	NA
DOMU	Issuer	42.19%	26.82%	36%	NA
RONW	Peer Group				
	Kerala Ayurveda Ltd	-49.30	19.89	-0.95%	NA
N7 4 X7	Issuer	23.81	91.08	77.33	NA
NAV per share based on balance sheet	Peer Group				
	Kerala Ayurveda Ltd	9.51	13.76	35.22	NA

14. Any other material information

- i. Jeena Sikho Lifecare Limited has informed the Exchange about the proposal to establish new branch of Jeena Sikho Lifecare Limited Hospitals in Raigad District, Maharashtra as a part of our ongoing efforts to expand our healthcare network and offer quality medical services to a larger population, in line with our strategic objectives.
- ii. Jeena Sikho Lifecare Limited has informed the Exchange that Jeena Sikho Lifecare Limited Hospital situated at Safdarjung (New Delhi) have empanelled with Govt. of Karnataka for providing OPD, IPD services and Panchkarma treatment to Karnataka bhavan officers/employees on CGHS rates cash basis.
- iii. Jeena Sikho Lifecare Limited has informed the Exchange regarding ' Jeena Sikho Lifecare Limited has informed the Exchange regarding that it has conducted a press conference at Khasra No. 346 and others, Upper Ganga Canal, Village Nagla Kumbha, District Meerut, Uttar Pradesh- 250002 (Jeena Sikho Lifecare Limited, Meerut Hospital) with Cancer Patients Recovering through Ayurveda and Natural Medicine.
- iv. Jeena Sikho Lifecare Limited has informed the Exchange regarding Empanelment of Ayurveda Panchkarma Hospital with SBI General Health Insurance for providing Cashless Ayurveda Panchkarma Treatment.
- v. Jeena Sikho Lifecare Limited has informed the Exchange regarding receiving an award from Smt. Rekha Gupta, the Chief Minister of Delhi in the programme organised on 20th March 2025 by Bharat 24 Channel in New Delhi.
- vi. Jeena Sikho Lifecare Limited has informed the Exchange regarding Appointment of M/s. Rawal & Co., Company Secretaries, as a Secretarial Auditor of

the Company for the Financial year 2024-25 and M/s. Deepak K Garg and Associates as an Internal Auditor of the Company for the Financial year 2024-25.

vii. Jeena Sikho Lifecare Limited has informed the Exchange about Incorporation of subsidiary Company i.e. Jeena Green Resources Private Limited.

viii. Jeena Sikho Lifecare Limited has informed the Exchange about the proposal to Incorporate Limited Liability Company (the LLC) at Sharjah Media City (SHAMS) Free Zone in United Arab Emirates under the name Jeena Sikho International LLC or any other name approved by the applicable Department/regulatory authority of UAE.

Note: For further updates and information, please refer stock exchange websites i.e. www.nseindia.com